Wednesday, July 8, 2026

Patent intelligence · US

US 10774330

Reduced size self-delivering RNAI compounds

granted A61PA61P1/16A61P11/00A61P13/12
Status granted
Pipeline programs 2
Years to expiry 14
Applicant portfolio 39
Patent details — US 10774330
Jurisdiction
US
Status
granted
Grant date
Sep 15, 2020
Expiration
Sep 10, 2040
Claims
19
CPC classes
A61P, A61P1/16, A61P11/00, A61P13/12
View on Google Patents ↗

Quick answer

US 10774330 (Reduced size self-delivering RNAI compounds) is held by Phio Pharmaceuticals Corp.. Status: granted. Granted Sep 15, 2020. Expires Sep 10, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
19
CPC classes
A61P, A61P1/16, A61P11/00, A61P13/12, A61P17/00, A61P17/02

More from Phio Pharmaceuticals Corp.

Related pharmaceutical patents in our USPTO index.

  1. US 11926828

    Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1

    Phio Pharmaceuticals Corp. · Expires Mar 7, 2044

    granted
  2. US 11639359

    Bryoid compositions, methods of making and use thereof

    Aphios Corporation · Expires Apr 27, 2043

    granted
  3. US 11584933

    RNA interference in ocular indications

    Phio Pharmaceuticals Corp. · Expires Feb 16, 2043

    granted
  4. US 11396654

    Neutral nanotransporters

    Phio Pharmaceuticals Corp. · Expires Jul 21, 2042

    granted
  5. US 11279934

    Methods for treating cancer using nucleic acids targeting MDM2 or MYCN

    Phio Pharmaceuticals Corp. · Expires Mar 17, 2042

    granted
  6. US 11254940

    Inhibition of MAP4K4 through RNAi

    Phio Pharmaceuticals Corp. · Expires Feb 17, 2042

    granted
  7. US 11234932

    Combination HIV therapeutic

    Aphios Corporation · Expires Jan 27, 2042

    granted
  8. US 11118178

    Reduced size self-delivering RNAI compounds

    Phio Pharmaceuticals Corp. · Expires Sep 9, 2041

    granted

Frequently asked questions

What is US patent 10774330?

US 10774330 (Reduced size self-delivering RNAI compounds) is held by Phio Pharmaceuticals Corp.. Status: granted. Granted Sep 15, 2020. Expires Sep 10, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10774330?

Phio Pharmaceuticals Corp. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 39 pharmaceutical patents for this assignee.

When does US 10774330 expire?

Our index shows an expiration date of Sep 10, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.